^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EO-3021

    i
    Other names: EO-3021, CPO102, SYSA1801, CPO 102, EO 3021, SYSA 1801, CPO-102, EO3021, SYSA-1801
    Company:
    CSPC Pharma, Elevation Oncology
    Drug class:
    Microtubule inhibitor, CLDN18.2-targeted antibody-drug conjugate
    Related drugs:
    1m
    Comparative analysis of the efficacy and safety of antibody‑drug conjugates, radionuclide‑drug conjugates and their combination targeting claudin 18.2 in gastric cancer treatment. (PubMed, Oncol Rep)
    In an NUGC‑4‑CLDN18.2 xenograft tumor model, the antitumor efficacy and toxicity of the mAb (SYSA1801mAb), as well as the ADC (SYSA1801) and RDC ([177Lu]Lu‑DOTA‑SYSA1801mAb), and their combinations in different sequences (ADC→RDC and RDC→ADC), were systematically assessed...Furthermore, sequential combination therapy that starts with ADC appears to be more favorable than approaches that start with RDC. Although ADC→RDC sequential therapy did not significantly outperform ADC monotherapy in this model, it may serve as an effective subsequent treatment strategy.
    Clinical • Journal
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    EO-3021
    5ms
    ELVCAP-002-01: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 (clinicaltrials.gov)
    P1, N=88, Terminated, Elevation Oncology | Trial completion date: Dec 2028 --> Jun 2025 | Recruiting --> Terminated | Trial primary completion date: Sep 2028 --> May 2025; Business Decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    Cyramza (ramucirumab) • Jemperli (dostarlimab-gxly) • EO-3021
    almost2years
    A phase I study of EO-3021 in adult patients with solid tumors likely to express CLDN18.2. (ASCO-GI 2024)
    41, 2023. Clinical trial information: NCT05980416.
    Clinical • P1 data
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    EO-3021
    2years
    Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers (clinicaltrials.gov)
    P1, N=0, Withdrawn, Conjupro Biotherapeutics, Inc. | N=72 --> 0 | Trial completion date: Mar 2025 --> Nov 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Feb 2025 --> Nov 2022
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN1 positive
    |
    EO-3021
    over2years
    Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 (clinicaltrials.gov)
    P1, N=120, Recruiting, Elevation Oncology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    EO-3021
    over2years
    Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 (clinicaltrials.gov)
    P1, N=120, Not yet recruiting, Elevation Oncology
    New P1 trial
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    EO-3021
    over2years
    First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors. (ASCO 2023)
    SYSA1801 shows promising early signs of efficacy with a well-tolerated safety profile in pts with CLDN18.2-expressing resistant/refractory solid tumors, especially GC. Part 1 of the study is ongoing with part 2 to start when the optimized dose is determined in China; studies outside of Greater China including in the United States are being planned by Elevation Oncology. Clinical trial information: NCT05009966.
    Clinical • P1 data
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    EO-3021
    4years
    Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor (clinicaltrials.gov)
    P1, N=272, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    EO-3021
    4years
    Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Conjupro Biotherapeutics, Inc.
    Clinical • New P1 trial
    |
    CLDN18 (Claudin 18)
    |
    EO-3021
    over4years
    Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor (clinicaltrials.gov)
    P1, N=272, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    Clinical • New P1 trial
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    EO-3021